| Analysis of pharmacology data and the prediction of adverse drug reactions and off‐target effects from chemical structure A Bender, J Scheiber, M Glick, JW Davies, K Azzaoui, J Hamon, L Urban, ... ChemMedChem: Chemistry Enabling Drug Discovery 2 (6), 861-873, 2007 | 393 | 2007 |
| How similar are similarity searching methods? A principal component analysis of molecular descriptor space A Bender, JL Jenkins, J Scheiber, SCK Sukuru, M Glick, JW Davies Journal of chemical information and modeling 49 (1), 108-119, 2009 | 347 | 2009 |
| Targeting acetylcholinesterase to treat neurodegeneration U Holzgrabe, P Kapková, V Alptüzün, J Scheiber, E Kugelmann Expert opinion on therapeutic targets 11 (2), 161-179, 2007 | 246 | 2007 |
| Mapping adverse drug reactions in chemical space J Scheiber, JL Jenkins, SCK Sukuru, A Bender, D Mikhailov, M Milik, ... Journal of medicinal chemistry 52 (9), 3103-3107, 2009 | 200 | 2009 |
| Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis J Scheiber, B Chen, M Milik, SCK Sukuru, A Bender, D Mikhailov, ... Journal of chemical information and modeling 49 (2), 308-317, 2009 | 193 | 2009 |
| Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity SCK Sukuru, JL Jenkins, REJ Beckwith, J Scheiber, A Bender, ... Journal of biomolecular screening 14 (6), 690-699, 2009 | 90 | 2009 |
| Understanding false positives in reporter gene assays: in silico chemogenomics approaches to prioritize cell-based HTS data TJ Crisman, CN Parker, JL Jenkins, J Scheiber, M Thoma, ZB Kang, ... Journal of chemical information and modeling 47 (4), 1319-1327, 2007 | 77 | 2007 |
| Which aspects of HTS are empirically correlated with downstream success? A Bender, D Bojanic, JW Davies, TJ Crisman, D Mikhailov, J Scheiber, ... Current Opinion in Drug Discovery and Development 11 (3), 327, 2008 | 74 | 2008 |
| Aziridide‐Based Inhibitors of Cathepsin L: Synthesis, Inhibition Activity, and Docking Studies R Vicik, M Busemann, C Gelhaus, N Stiefl, J Scheiber, W Schmitz, ... ChemMedChem: Chemistry Enabling Drug Discovery 1 (10), 1126-1141, 2006 | 70 | 2006 |
| Interaction of (benzylidene-hydrazono)-1, 4-dihydropyridines with β-amyloid, acetylcholine, and butyrylcholine esterases V Alptüzün, M Prinz, V Hörr, J Scheiber, K Radacki, A Fallarero, P Vuorela, ... Bioorganic & medicinal chemistry 18 (5), 2049-2059, 2010 | 68 | 2010 |
| Charge interactions do the job: a combined statistical and combinatorial approach to finding artificial receptors for binding tetrapeptides in water C Schmuck, M Heil, J Scheiber, K Baumann Angewandte Chemie International Edition 44 (44), 7208-7212, 2005 | 46 | 2005 |
| “Virtual fragment linking”: an approach to identify potent binders from low affinity fragment hits TJ Crisman, A Bender, M Milik, JL Jenkins, J Scheiber, SCK Sukuru, ... Journal of medicinal chemistry 51 (8), 2481-2491, 2008 | 45 | 2008 |
| Cis‐Configured Aziridines Are New Pseudo‐Irreversible Dual‐Mode Inhibitors of Candida albicans Secreted Aspartic Protease 2 B Degel, P Staib, S Rohrer, J Scheiber, E Martina, C Büchold, K Baumann, ... ChemMedChem: Chemistry Enabling Drug Discovery 3 (2), 302-315, 2008 | 39 | 2008 |
| NMR spectroscopic and molecular modelling studies on cyclodextrin–dipeptide inclusion complexes C Kahle, R Deubner, C Schollmayer, J Scheiber, K Baumann, ... European journal of organic chemistry 2005 (8), 1578-1589, 2005 | 34 | 2005 |
| Comparison of cyclodextrin‐dipeptide inclusion complexes in the absence and presence of urea by means of capillary electrophoresis, nuclear magnetic resonance and molecular … B Waibel, J Scheiber, C Meier, M Hammitzsch, K Baumann, GKE Scriba, ... European journal of organic chemistry 2007 (18), 2921-2930, 2007 | 28 | 2007 |
| Use of ligand based models for protein domains to predict novel molecular targets and applications to triage affinity chromatography data A Bender, D Mikhailov, M Glick, J Scheiber, JW Davies, S Cleaver, ... Journal of proteome research 8 (5), 2575-2585, 2009 | 27 | 2009 |
| SARS‐CoV‐2 infections in cancer outpatients—Most infected patients are asymptomatic carriers without impact on chemotherapy L Hempel, A Piehler, MW Pfaffl, J Molnar, B Kirchner, S Robert, J Veloso, ... Cancer Medicine 9 (21), 8020-8028, 2020 | 17 | 2020 |
| Ladungswechselwirkungen machen es möglich: ein kombinierter statistischer und kombinatorischer Ansatz zur Auffindung künstlicher Rezeptoren für die Bindung von Tetrapeptiden in … C Schmuck, M Heil, J Scheiber, K Baumann Angewandte Chemie 117 (44), 7374-7379, 2005 | 14 | 2005 |
| xMaP An Interpretable Alignment-Free Four-Dimensional Quantitative Structure–Activity Relationship Technique Based on Molecular Surface Properties and Conformer Ensembles J Dreher, J Scheiber, N Stiefl, K Baumann Journal of Chemical Information and Modeling 58 (1), 165-181, 2018 | 12 | 2018 |
| Chemogenomic analysis of safety profiling data J Scheiber, JL Jenkins Chemogenomics: Methods and Applications, 207-223, 2009 | 11 | 2009 |
Jeremy L. JenkinsUS Head Discovery Sciences, Novartis BioMedical ResearchVerified email at novartis.com
